The KEYNOTE-811 trial demonstrated that pembrolizumab combined with trastuzumab and chemotherapy significantly improved PFS in HER-2 positive metastatic gastric/gastroesophageal junction adenocarcinoma patients with PD-L1 CPS ≥ 1. This evidence concerns the gene CD274 and gastroesophageal junction adenocarcinoma.